Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience

Basit Öğe Kaydı
dc.authorwosidGönülal, Melis/ABW-6872-2022
dc.contributor.authorGonulal, Melis
dc.contributor.authorBalci, Didem Didar
dc.contributor.authorOzturk, Aylin
dc.contributor.authorDogan, Sinan
dc.date.accessioned2024-03-09T18:48:30Z
dc.date.available2024-03-09T18:48:30Z
dc.date.issued2023
dc.departmentİzmir Bakırçay Üniversitesien_US
dc.description.abstractBackground This work aimed to investigate the long-term clinical experience with ustekinumab in cases with psoriasis. Materials and methods This retrospective cohort research group consisted of cases who presented to the dermatology outpatient clinics between January 2015 and January 2021, diagnosed with psoriasis, and were treated with ustekinumab. Data including gender, age, weight, disease duration, naive and non-naive status, psoriasis type, duration of medication, comorbidities, psoriasis area and severity index scores, the causes of treatment discontinuation, and previous treatments were retrospectively reviewed and analyzed. Results 160 cases with psoriasis were treated with ustekinumab during the research period. Twenty-four patients were excluded. Among 136 cases, 84 (61.8%) were male and 52 (38.2%) were female. We determined 80.55% of the non-naive cases responded to ustekinumab. Conclusion Ustekinumab can be a suitable treatment option for non-naive and resistant patients. Our data suggest the positive effect persists in cases with favorable responses to the first or second dose of ustekinumab. Also, we determined male cases gave more rapid and more robust responses than female cases, and patients were more willing about continuing the treatment.en_US
dc.identifier.doi10.1080/09546634.2023.2241941
dc.identifier.issn0954-6634
dc.identifier.issn1471-1753
dc.identifier.issue1en_US
dc.identifier.pmid37533359en_US
dc.identifier.scopus2-s2.0-85166420198en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1080/09546634.2023.2241941
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1351
dc.identifier.volume34en_US
dc.identifier.wosWOS:001040063400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Dermatological Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPsoriasis; Ustekinumab; Biologicen_US
dc.titleEffectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1351.pdf
Boyut:
625.37 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu